PBAC's latest decision on Methylphenidate hydrochloride: Recommended with restriction (2022). Considered for Treatment of attention deficit hyperactivity disorder (ADHD) in adults with a retrospective diagnosis of ADHD (diagnosed after age 18).
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
5
first 2006
Submissions
5
2006 → 2022
Eligible population
Adults with attention deficit hyperactivity disorder diagnosed after age 18 years, who have demonstrated a response to immediate-release methylphenidate with no emergence of serious adverse events and require continuous coverage over 8 hours.
Therapy area
Neurology
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
lisdexamfetamine (LDX)
Economic model
Cost-minimisation
Budget impact
$30
ICER note
This is a Category 3 submission (flow-on listing change with pricing adjustment) based on prior PBAC decision for LDX in March 2020. No de novo economic evaluation or ICER was conducted; the submission is a cost-minimisation analysis comparing Ritalin LA pricing to LDX post-price-reduction.
ICER (historical)
$15k/QALY in an earlier submission (2006) — the latest submission carried no numeric base case. No single PSD states this combined range; see source PSDs.
Submission history
Mar 2006: Not recommended
Nov 2006: Recommended with restriction · Authority Required — ICER $15k/QALY
Jul 2012: Not recommended · Authority Required
Mar 2020: Recommended · Authority Required
Mar 2022: Recommended with restriction · Authority Required